- Home
- LTRN vs CVKD Comparison
LTRN vs CVKD Comparison
Compare LTRN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- CVKD
- Stock Information
- Founded
- LTRN 2013
- CVKD 2022
- Country
- LTRN United States
- CVKD United States
- Employees
- LTRN N/A
- CVKD N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- LTRN Health Care
- CVKD Health Care
- Exchange
- LTRN Nasdaq
- CVKD Nasdaq
- Market Cap
- LTRN 36.0M
- CVKD 29.5M
- IPO Year
- LTRN 2020
- CVKD 2023
- Fundamental
- Price
- LTRN $4.99
- CVKD $11.15
- Analyst Decision
- LTRN Strong Buy
- CVKD Strong Buy
- Analyst Count
- LTRN 1
- CVKD 1
- Target Price
- LTRN $25.00
- CVKD $32.00
- AVG Volume (30 Days)
- LTRN 410.2K
- CVKD 27.6K
- Earning Date
- LTRN 08-19-2025
- CVKD 08-19-2025
- Dividend Yield
- LTRN N/A
- CVKD N/A
- EPS Growth
- LTRN N/A
- CVKD N/A
- EPS
- LTRN N/A
- CVKD N/A
- Revenue
- LTRN N/A
- CVKD N/A
- Revenue This Year
- LTRN N/A
- CVKD N/A
- Revenue Next Year
- LTRN N/A
- CVKD N/A
- P/E Ratio
- LTRN N/A
- CVKD N/A
- Revenue Growth
- LTRN N/A
- CVKD N/A
- 52 Week Low
- LTRN $2.55
- CVKD $5.70
- 52 Week High
- LTRN $6.12
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- LTRN 65.68
- CVKD 48.44
- Support Level
- LTRN $4.05
- CVKD $10.14
- Resistance Level
- LTRN $5.74
- CVKD $11.44
- Average True Range (ATR)
- LTRN 0.47
- CVKD 0.75
- MACD
- LTRN 0.07
- CVKD 0.07
- Stochastic Oscillator
- LTRN 62.56
- CVKD 74.38
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.